BioCryst Pharmaceuticals Q2 Earnings Call Highlights
· finance.yahoo.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie Ga
BioCryst began shipping ORLADEYO oral pellets for pediatric patients during the week of the call. Gayer said the company had received 47 prescriptions through J...